Aurinia Pharmaceuticals Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing was signed February 14, 2024. Aurinia is a biopharmaceutical company whose commercial business is primarily its lupus nephritis (LN) treatment LUPKYNIS (voclosporin); U.S. sales are complemented by collaboration activity with Otsuka outside the United States.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Product revenue, net | $158.5 million | $103.5 million | +$55.1 million |
| License, collaboration and royalty revenue | $17.0 million | $30.6 million | −$13.6 million |
| Total revenue, net | $175.5 million | $134.0 million | +$41.5 million |
| Cost of sales | $14.1 million | $5.7 million | +$8.5 million |
| Gross margin | Approximately 92% | Approximately 96% | Down 4 percentage points |
| Operating expenses, including cost of sales | $267.2 million | $245.5 million | +$21.7 million |
| Loss from operations | $(91.7) million | $(111.5) million | Loss narrowed $19.8 million |
| Net loss | $(78.0) million | $(108.2) million | Loss narrowed $30.2 million |
| Basic and diluted loss per share | $(0.54) | $(0.76) | Improved $0.22 |
| Net cash used in operating activities | $(33.5) million | $(79.5) million | Cash use decreased $46.1 million |
- Revenue mix and growth: U.S. product revenue growth was attributed primarily to greater LUPKYNIS market penetration. The company reported 1,791 patient start forms in 2023 versus 1,650 in 2022, approximately 2,066 patients on therapy at year-end versus 1,525 a year earlier, and 12-month persistency of approximately 55% versus 50%.
- Profitability and expenses: SG&A was $195.0 million, nearly unchanged from $196.4 million. R&D increased to $49.6 million from $45.0 million, mainly due to higher share-based compensation. Cost of sales rose with product sales and amortization of the monoplant finance right-of-use asset. Interest income increased to $17.0 million from $5.1 million, partly offsetting operating losses; 2023 also included $2.8 million interest expense.
- Cash, investments and working capital: At year-end, cash, cash equivalents and restricted cash were $48.9 million, with investments of $301.8 million; working capital was $347.6 million. Combined cash and investments totaled approximately $350.7 million, compared with $389.4 million at year-end 2022. Management said this position was sufficient to fund current plans for at least the next few years.
- Debt and lease obligations: The filing reports no conventional borrowings in the supplied financial statements. A CHF-denominated monoplant finance lease produced a $90.1 million lease liability at year-end, including $14.6 million current and $75.5 million non-current. The related right-of-use asset was $108.7 million. The company recorded $5.9 million of foreign-exchange loss from revaluation of the lease liability.
- Other balance-sheet items: Total assets were $548.1 million and total liabilities $170.1 million. Accumulated deficit was $942.3 million. Inventory was $39.7 million, up from $24.8 million; the company recorded a $0.9 million inventory write-down in 2023.
- Fourth quarter: Total revenue was $45.1 million, operating loss was $29.7 million, net loss was $26.9 million and loss per share was $0.19. Quarterly revenue included a $10.0 million Otsuka pricing-and-reimbursement milestone recognized earlier in the year, not in Q4.
Material changes versus 2022
- Product revenue increased approximately 53%, while collaboration revenue declined because 2022 included a $30.0 million European regulatory milestone; 2023 included a $10.0 million pricing-and-reimbursement milestone.
- Operating cash outflow narrowed substantially, primarily due to increased receipts from LUPKYNIS sales. Cash and investments together declined by approximately $38.7 million year over year.
- Gross margin decreased from approximately 96% to 92%, reflecting higher cost of sales and monoplant-related amortization.
- Operating loss and net loss narrowed, despite higher total operating expenses, supported by increased product revenue and interest income.
- The monoplant entered its finance-lease accounting period in 2023, adding significant lease assets and liabilities, amortization, interest expense and CHF exchange-rate exposure.
Outlook, management commentary and risks
- Post-year-end restructuring: On February 14, 2024, the Board concluded its strategic review and decided to discontinue future development of AUR200 and AUR300, prioritizing LUPKYNIS commercialization and operating efficiency. The company expected a one-time first-quarter 2024 charge of approximately $11–$15 million, annual cost savings of approximately $50–$55 million, and at least a 25% workforce reduction by the end of Q1 2024. Management expected about 75% of the savings to be realized in 2024, excluding the one-time charge, and said commercial investment was not planned to be reduced.
- Capital allocation: The Board approved a share repurchase program of up to $150 million, subject to Canadian regulatory relief for the full amount. Without that relief, the company said Canadian rules could limit purchases under the stated exemption to 5% of outstanding shares. Repurchases were expected to begin around February 21, 2024; the filing does not establish that the full authorization would be used.
- Commercial and partnership developments: LUPKYNIS received Swiss approval in April 2023; Otsuka secured a pricing-and-reimbursement milestone in 2023 and filed a Japanese NDA in November. Aurinia may receive an additional $10.0 million milestone related to Japanese regulatory approval, subject to achievement. Otsuka royalties are tiered at 10%–20% of eligible net sales.
- Development and regulatory obligations: Remaining FDA post-marketing requirements include pediatric studies expected to be completed in 2025 and 2031. The company expects regulatory approval for the monoplant and a backup encapsulation site in 2025. These remain subject to regulatory and operational execution.
- Key risks: Aurinia depends heavily on a single marketed product, two U.S. specialty-pharmacy customers and Otsuka; those customers represented approximately 99% of 2023 revenue together. It also relies on sole-source suppliers for drug substance and capsule encapsulation. Other material risks include reimbursement and drug-pricing pressure, product adoption and persistence, competition, clinical and post-marketing obligations, manufacturing continuity, patent challenges, and execution of the restructuring.
- Patent and generic exposure: U.S. new-chemical-entity exclusivity runs to January 2026. The original composition-of-matter patent term extension remains under review; interim extension currently runs to October 17, 2024. The company cites Orange Book-listed dosing patents with terms to 2037, while noting generic applicants may file ANDAs as early as January 2025.
- Contingencies: A purported shareholder class action alleging misleading statements about financial guidance and commercial prospects remained pending; Aurinia filed a motion to dismiss and stated it intended to defend the case. Management said it did not expect the ultimate resolution of contingencies to materially adversely affect the financial statements. Firm Lonza manufacturing commitments were approximately $11.0 million through 2024.
- Accounting and controls: Management and the external auditor concluded internal control over financial reporting was effective as of December 31, 2023. No material adjustment to product-revenue variable-consideration estimates was reported for 2023.
Important facts for investors to verify
- Whether LUPKYNIS prescription growth, patient persistence and actual net sales continue to support revenue growth, bearing in mind the company cautions that patient activity metrics do not directly predict revenue.
- How much of the announced $50–$55 million annual savings is realized, when savings appear in reported results, and whether the $11–$15 million restructuring charge or workforce reductions differ from estimates.
- Whether Canadian regulatory relief permits the intended $150 million repurchase and how actual repurchases affect available liquidity and share count.
- The status of the Japanese NDA, related milestone conditions, and the pace of Otsuka commercialization and royalties in its territories.
- The USPTO decision on the voclosporin patent-term-extension application, the interim extension deadline, and any generic filings or patent challenges.
- Cash burn and liquidity after restructuring, share repurchases, lease payments, inventory commitments and post-marketing requirements; management’s “at least the next few years” funding statement is forward-looking.
- Supply continuity and planned 2025 approvals for the monoplant and backup encapsulation facility, given the current reliance on single-source manufacturers.